Airsculpt Technologies Inc (AIRS)vsEli Lilly and Company (LLY)
AIRS
Airsculpt Technologies Inc
$2.54
+2.83%
HEALTHCARE · Cap: $174.25M
LLY
Eli Lilly and Company
$851.21
+9.80%
HEALTHCARE · Cap: $760.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 42832% more annual revenue ($65.18B vs $151.82M). LLY leads profitability with a 31.7% profit margin vs -7.7%. LLY earns a higher WallStSmart Score of 78/100 (B+).
AIRS
Hold36
out of 100
Grade: F
LLY
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.9%
Fair Value
$7.04
Current Price
$2.54
$4.50 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 200.0% YoY
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
Areas to Watch
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -14.1% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 28.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AIRS
The strongest argument for AIRS centers on EPS Growth, Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bear Case : AIRS
The primary concerns for AIRS are Market Cap, Debt/Equity, Piotroski F-Score.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Key Dynamics to Monitor
AIRS profiles as a turnaround stock while LLY is a growth play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.27 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 36/100), backed by strong 31.7% margins and 42.6% revenue growth. AIRS offers better value entry with a 69.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is a leader in the aesthetic medical technology field, recognized for its proprietary AirSculpt® procedure, which offers minimally invasive body contouring solutions while emphasizing patient safety and comfort. The company boasts a growing network of licensed practitioners and a strong focus on technological innovation, positioning itself advantageously in the expanding market for non-invasive cosmetic treatments. By responding to the rising global demand for aesthetic procedures, Airsculpt aims to enhance its market share and diversify its service offerings, thereby fostering both immediate growth and sustainable long-term value for investors.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?